In vitro effects of trapidil on fatty acid and prostaglandin metabolism in platelets.
The effects of trapidil, a coronary vasodilator and platelet aggregation inhibitor, on fatty acid metabolism and prostaglandin (PG) formation in platelets were studied using platelet suspensions from six normal subjects. The addition of trapidil to fatty acids in platelet phospholipids decreased palmitoleic acid and arachidonic acid, and increased an unidentified substance, X2 (palmitoleic acid, P < 0.05; arachidonic acid, P < 0.05; X2, P < 0.05). Thrombin stimulation following the addition of trapidil resulted in an increase in stearic acid and a decrease in arachidonic acid, compared with the trapidil-free control samples (stearic acid, P < 0.05; arachidonic acid, P < 0.02). The addition of trapidil tended to increase immunoreactive PGE (iPGE) and iPGF dose-dependently. On the other hand, thrombin stimulation following the addition of trapidil decreased the formation of thromboxane B2 (TXB2) significantly compared with the levels of TXB2 in the trapidil-free samples (10 micrograms/mL trapidil, P < 0.005, 100 micrograms/mL trapidil, P < 0.001). These results show that trapidil increased arachidonic acid mobilization in the platelets.
Tohjima
T
T
Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Arisaka
T
T
Honda
N
N
D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D005227:Fatty Acids / Q000097:blood*; D006801:Humans; D066298:In Vitro Techniques; D010743:Phospholipids / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011453:Prostaglandins / Q000097:blood*; D011863:Radioimmunoassay; D013917:Thrombin / Q000494:pharmacology; D013929:Thromboxane B2 / Q000378:metabolism; D014192:Trapidil / Q000494:pharmacology*
D005227:Fatty Acids; D010743:Phospholipids; D010975:Platelet Aggregation Inhibitors; D011453:Prostaglandins; D013929:Thromboxane B2; D013917:Thrombin; D014192:Trapidil